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Abstract
Context—Maternal pregestational diabetes (PGDM) is a risk factor for development of 
congenital heart defects (CHDs). Glycemic control before pregnancy reduces the risk of CHDs. A 
meta-analysis was used to estimate summary ORs and mathematical modeling was used to 
estimate population attributable fractions (PAFs) and the annual number of CHDs in the U.S. 
potentially preventable by establishing glycemic control before pregnancy.
Evidence acquisition—A systematic search of the literature through December 2012 was 
conducted in 2012 and 2013. Case–control or cohort studies were included. Data were abstracted 
from 12 studies for a meta-analysis of all CHDs.
Evidence synthesis—Summary estimates of the association between PGDM and CHDs and 
95% credible intervals (95% CrIs) were developed using Bayesian random-effects meta-analyses 
for all CHDs and specific CHD subtypes. Posterior estimates of this association were combined 
with estimates of CHD prevalence to produce estimates of PAFs and annual prevented cases. 
Ninety-five percent uncertainty intervals (95% UIs) for estimates of the annual number of 
preventable cases were developed using Monte Carlo simulation. Analyses were conducted in 
2013. The summary OR estimate for the association between PGDM and CHDs was 3.8 (95% 
CrI=3.0, 4.9). Approximately 2670 (95% UI=1795, 3795) cases of CHDs could potentially be 
prevented annually if all women in the U.S. with PGDM achieved glycemic control before 
pregnancy.
Conclusions—Estimates from this analysis suggest that preconception care of women with 
PGDM could have a measureable impact by reducing the number of infants born with CHDs.
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Introduction
Congenital heart defects (CHDs) collectively are the most common birth defect, affecting 
approximately 80 per 10,000 births annually in the U.S.1 CHDs account for significant 
infant morbidity and mortality, causing approximately 2.4 deaths per 10,000 live births in 
U.S. each year.2,3 Women with diabetes before pregnancy, that is, pregestational diabetes 
mellitus (PGDM), have 2–5 times the risk of having a CHD-affected pregnancy compared to 
women without diabetes4–7; however, the magnitude of the association varies among studies 
and by CHD phenotype.5,6,8–10 The major teratogen in diabetic pregnancies is presumed to 
be hyperglycemia caused by poor glycemic control during organogenesis.11 Potential 
mechanisms for hyperglycemia-induced birth defects include decreased levels of inositol, 
arachidonic acid metabolic disturbances, increased oxidative stress, and alterations in gene 
expression.12–14 Some studies suggest that the excess risk can be eliminated with optimal 
diabetes management prior to and during early pregnancy.8,13,15–17
Results from a previous meta-analysis indicated an increased risk of specific CHDs in 
pregnancies affected by type 1 diabetes mellitus, but studies included were limited to those 
published before 2002.4 Other meta-analyses have suggested that hyperglycemia increases 
adverse effects in pregnancies affected by type 1 and type 2 diabetes,18 and that 
preconception care can be effective in establishing glycemic control prior to pregnancy and 
improving maternal and fetal outcomes, including reducing the risk of congenital 
anomalies.19–21 Establishing glycemic control prior to and early in pregnancy may decrease 
the risk of having a CHD-affected pregnancy, possibly to the same level as pregnancies not 
affected by diabetes.8,13,15–17 However, only 40%–60% of women with PGDM are 
estimated to achieve glycemic control prior to pregnancy.22,23 Given the effectiveness of 
diabetes management before and early in pregnancy, it may be possible to reduce the annual 
number of cases of CHD occurring as a consequence of PGDM.
The prevalence of type 1 and type 2 diabetes has increased in the U.S. among men and 
women of all ages,24,25 including reproductive-aged women and women who become 
pregnant. The majority of this increase is likely due to increased prevalence of type 2 
diabetes.26,27 Among women at risk of becoming pregnant, diabetes prevalence estimates 
vary from 1.9% to 4.0%,24,26 with prevalence varying by race, age, and SES. An additional 
0.5%–1% of reproductive-aged women with diabetes have not been diagnosed and are not 
being clinically managed.24,28,29
The objectives of this study were to conduct a systematic review and meta-analysis to 
estimate the magnitude of the association between PGDM and CHDs (all CHDs and specific 
subtypes), and to use these results to estimate population attributable fractions (PAFs) and 
the annual number of CHDs that could potentially be prevented in the U.S. with established 
glycemic control in women with PGDM prior to and early in pregnancy.
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Evidence Acquisition
Systematic Review
CDC librarians conducted literature searches of Medline, Embase, Cumulative Index to 
Nursing and Allied Health Literature (CINAHL), and Population Information Online 
(POPLINE) in April 2012 to obtain published estimates of the associations of PGDM with 
all CHDs and specific CHDs. This search was repeated in March 2013 to include all 
publications through December 2012. Each database was searched for studies published 
from database inception through December 2012. The search strategy used keywords that 
combined diabetes, CHDs, and pregnancy (Appendix, available online).
Papers were considered for inclusion if they were in English, included women with PGDM, 
included a comparison group of women without a diagnosis of PGDM, contained one or 
multiple CHDs as an outcome, were case–control or cohort studies, and were retrospective 
or prospective. Papers were excluded if they did not include CHDs (n=151), were not 
original research studies (e.g., editorials, conference abstracts; n=325), had estimates of 
diabetes exposure limited to or including gestational diabetes without the capacity to 
separate PGDM (n=29), did not include PGDM as an exposure (women with PGDM were 
excluded or papers did not include a measure of PGDM; n=27), did not have an unexposed 
comparison group (n=222), did not exclude chromosomal and genetic defects from estimates 
of CHDs (n=7), or did not include a study sample that was a representative population (e.g., 
only women aged older than 40 years, only women at increased risk of having an infant with 
a CHD [e.g., because of family history, previous infant with CHD], only women with parity 
greater than six, only women experiencing pregnancy complications and in which the CHD 
was a secondary outcome; n=11).
The search yielded 3,455 references, with 103 articles identified as duplicates and excluded. 
Two co-authors (J.A.M., R.M.S.) independently screened each title and abstract. Based on 
title and abstract, 2,548 references were excluded, leaving 804 references for full-text 
review. Full texts were reviewed independently by the same co-authors (J.A.M., R.M.S.). 
Reference lists of full-text articles were searched for additional references. A third co-author 
(S.M.G.) resolved any decisions regarding whether an article’s data should be abstracted 
(n=23). After review, 766 articles were excluded and 39 articles were abstracted (including 
one that had been previously identified) (Figure 1).
Using a standard abstraction form created in Microsoft Word (Redmond WA), two co-
authors (J.A.M., R.M.S.) independently abstracted data from each article, including 
information on the type of study (case–control or cohort), method of data collection 
(retrospective or prospective), study population, population size, type of comparison group, 
type of diabetes (type 1, type 2, or not specified), type of CHD, type of results available 
(crude or adjusted), and counts of exposed/unexposed CHD cases. Crude data were 
abstracted from each article and unadjusted ORs or risk ratios (RRs) and 95% CIs were 
calculated as effect estimates for each study. Data were entered into a Microsoft Excel 
spreadsheet and discrepancies were identified and resolved by J.A.M. and R.M.S. Different 
subsets of articles were used for analyses of total CHDs and individual CHDs. Estimates 
from overlapping study populations, CHDs with fewer than three published effect estimates 
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for the association with PGDM, and CHDs with at least three published effect estimates, but 
in which the effect estimates were too heterogeneous to obtain stable summary estimates in 
the meta-analysis were excluded. For studies with overlapping study populations, only the 
largest or most recent study was included in the analysis (Figure 1). Owing to the limited 
number of studies with effect estimates for CHDs, no formal analysis of study bias was 
conducted. However, exclusion criteria were intended to minimize bias in study design and 
ensure that well-designed, population-based studies were included in the meta-analysis. 
After exclusions, 12 studies contributed to the meta-analysis for all CHDs,5,6,8,10,30 –37 and 
three to five studies contributed data to the meta-analysis for the five individual CHDs 
assessed (Appendix Table 1, available online; Figure 1).5,6,8–10,38
Measures of the association with PGDM were available for eight individual CHDs from at 
least three studies; meta-analyses were conducted for five of these defects: atrioventricular 
septal defect (AVSD), coarctation of the aorta, hypoplastic left heart syndrome (HLHS), 
tetralogy of Fallot (ToF), and transposition of the great arteries (TGA). Unadjusted ORs or 
RRs were estimated for each study and used for the meta-analyses. Meta-analyses were not 
conducted for ventricular septal defects, atrial septal defects, and truncus arteriosus because 
of the small number of studies focused on these outcomes or the extensive heterogeneity of 
the effect estimates among the reported results, which may suggest systematic ascertainment 
bias among the different studies (Figure 1).
Prevalence of Selected Congenital Heart Defects and Annual Number of Expected 
Outcomes
National prevalence estimates for TGA, ToF, HLHS, and AVSD were obtained from a 
publication of 2004–2006 data from pooled state birth defect surveillance programs (Table 
1).39 Because prevalence estimates of total CHDs and coarctation of the aorta were not 
available from this publication, estimates for total CHDs and coarctation of the aorta were 
estimated from an evaluation from the Metropolitan Atlanta Congenital Defects Program 
(MACDP) and were assumed to be nationally representative (Table 1).1 Race-specific 
prevalence estimates were also obtained from a recent evaluation from the MACDP.40 SEs 
for prevalence estimates of each CHD were estimated by assuming that the reported 
prevalence values were samples from a normal distribution. The annual number of U.S. 
cases were estimated by multiplying estimated prevalence by the number of U.S. live births 
in 2011 (n=3,953,590), the most recent year for which final birth data were available (Table 
1).41 Race-specific number of cases were estimated by multiplying race-specific estimated 
prevalence by number of U.S. live births in 2011 (non-Hispanic white, n=2,146,566; non-
Hispanic black, n=582,345; and Hispanic, n=918,129).41
Evidence Synthesis
Meta-Analysis
A Bayesian approach, with study-level random effects to account for inter-study 
heterogeneity, was used to summarize data on the association between PGDM and CHDs. 
Posterior estimates were developed using Markov Chain Monte Carlo methods and 
summarized using posterior medians and equal-tailed 95% credible intervals (95% 
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CrIs).42,43 Models were not adjusted for maternal characteristics such as age, parity, or race. 
Details on the models and the estimation process used in the meta-analysis are given in the 
Appendix (available online). The meta-analysis was conducted using WinBUGS, version 
1.4.3.
Sensitivity Analyses
A series of alternative meta-analysis models were evaluated to assess the sensitivity of 
results to underlying assumptions. For example, posterior estimates of the OR relating 
PGDM to all CHDs were estimated using alternative assumptions for the prior distributions 
of both the true OR and the study-level random effects. In addition, separate analyses were 
conducted to examine the potential impact of study design, cohort versus case–control, on 
the posterior OR estimates. Separate analyses were also conducted to examine the impact of 
restricting the meta-analysis only to studies that included both type 1 and type 2 diabetes. 
Because the studies selected for the meta-analysis spanned a wide range of years, a 
supplemental meta-analysis, limited to those studies published in 2000–2012, was also 
conducted. Details on the sensitivity assessment for the meta-analysis portion of the analyses 
are provided in the Appendix (available online); all sensitivity analyses were conducted in 
2013.
Prevalence of Pregestational Diabetes
Prevalence estimates of measured or self-reported PGDM are not available for large, 
population-based studies of women who had a pregnancy with or without a CHD. Therefore, 
overall and race-specific estimates of diabetes among women aged 20–44 years were 
obtained from Health Data Interactive software provided by the National Center for Health 
Statistics and used as a proxy for PGDM.28 Health Data Interactive utilizes data from the 
National Health and Nutrition Examination Survey and includes women, regardless of 
pregnancy status, surveyed in 2007–2010. Estimates include diagnosed and undiagnosed 
diabetes; diagnosed diabetes was defined as diabetes diagnosed by a doctor/health 
professional outside of pregnancy, and undiagnosed diabetes was defined as having fasting 
blood glucose ≥126 mg/dL or hemoglobin A1c ≥6.5%, but no diabetes diagnosis.44 Among 
all women, 3.2% (95% CI=2.5%, 4.0%) were estimated to have diabetes; by race, 2.7% 
(95% CI=1.8%, 4.1%) of non-Hispanic white, 4.6% (95% CI=3.3%, 6.4%) of non-Hispanic 
black, and 3.7% (95% CI=2.2%, 6.2%) of Hispanic women were estimated to have 
diabetes.28
Population Attributable Fraction and Estimated Preventable Number of Congenital Heart 
Defects with Elimination of Risk Associated with Pregestational Diabetes
The PAF for the number of CHDs due to PGDM was estimated using the model45:
where P[D] is the prevalence of diabetes among women at risk for pregnancy and OR is the 
estimate of the true OR relating PGDM and the CHD of interest developed in the meta-
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analysis.45 This model is adapted from the traditional estimate of the PAF using RRs and is 
used when the OR approximates the RR (when the disease is rare, as is the case with birth 
defects, and controls have been sampled from the nondiseased population). Race-specific 
diabetes prevalence was used to obtain race-specific PAFs. This model assumes no 
confounding of the diabetes–CHD association and that estimated effect estimates were not 
adjusted for potential confounders. The model did not control for maternal age, parity, or 
other maternal factors. The estimate for PAF was multiplied by the estimated race-specific 
annual number of births with CHD of various types to obtain the annual number of births 
attributable to PGDM. A key assumption in the approach to estimating PAFs and the 
attributable number of cases is that an intervention results in optimal glycemic control prior 
to pregnancy among all women with PGDM and reduces their CHD risk to that of 
nondiabetic women. Because complete reduction of the risk of PGDM-attributable CHD 
might be unrealistic, the impact assuming a 50% reduction in risk was also estimated. The 
same approach was used to produce race-specific and overall estimates of PAFs and the 
number of PGDM-attributable CHD cases. Although race-specific estimates of diabetes 
prevalence and the number of live births were used to develop the race-specific effects, a 
common estimate of the OR across race categories was used.
A Monte Carlo simulation was used to combine lack of knowledge concerning the true 
PGDM and CHD OR, as estimated by the posterior distribution for the parameter produced 
in the meta-analysis, with additional sources of uncertainty associated with the other inputs 
used to model PAF and the number of live births affected by CHD. The Monte Carlo 
process was used to propagate these various uncertainties through to the modeled estimates 
of PAF and number of prevented cases (Appendix, available online).46,47 The Monte Carlo 
simulations were implemented using SAS, version 9.3. All estimates of preventable numbers 
were rounded to the nearest multiple of five to avoid overstating the precision of these 
estimates.
For all CHDs, ORs and RRs from individual studies that were used in the meta-analysis of 
the association with PGDM ranged from estimates of 1.3 to 8.4. More variation was 
observed for individual CHDs, with ORs ranging from 1.3 for coarctation of the aorta to 
13.3 for AVSD (Appendix Table 1, available online). The estimated number of affected U.S. 
births per year for all CHDs was 32,182 (95% CI=31,075, 33,301). Of the individual CHDs 
included in the meta-analyses, the estimated annual number of U.S. births ranged from 909 
for HLHS to 1862 for AVSD (Table 1).
The summary OR for PGDM and all CHDs estimated in the meta-analysis was 3.8 (95% 
CrI=3.0, 4.9), based on 12 studies (Table 2). PGDM and AVSD had the largest summary 
OR (10.6), and PGDM and coarctation of the aorta had the smallest summary OR (3.7). The 
PAF for PGDM and total CHDs in the population was 8.3% (95% uncertainty interval 
[UI]=5.6%, 11.8%). Accounting for differences in the prevalence of PGDM by race, the 
PAF for PGDM and total CHDs ranged from 7.1% for non-Hispanic white to 11.5% for 
non-Hispanic black women (Table 2). Among women of all races, the PAF for PGDM with 
individual CHDs ranged from 7.9% for coarctation of the aorta to 23.4% for AVSD. In the 
U.S., for all CHDs considered in the analysis, reducing the risk for women with PGDM to 
that of women without PGDM could potentially reduce the annual number of CHD cases by 
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2670 (95% UI=1795, 3795) (Table 2); by CHD subtype, it could potentially prevent 435 
cases of AVSD, 140 cases of coarctation of the aorta, 75 cases of HLHS, 230 cases of ToF, 
and 130 cases of TGA. Assuming a 50% reduction in the risk of PGDM-associated CHDs, 
approximately 1,335 (95% UI=295, 485) PGDM-associated CHD cases could be prevented 
annually.
In some cases, posterior estimates have been shown to be sensitive to the form of the 
assumed prior distribution for the OR even when that prior appears to be non-informative. 
To assess this possibility, the estimated posterior distributions derived under a vague normal 
prior for the log OR, the primary result, were compared to those derived under a 
noninformative uniform prior for the log of the OR and a similarly noninformative uniform 
prior on the untransformed OR. In both cases, the selection of alternative forms for the prior 
on the OR had negligible effects on the posterior estimates. In addition, no difference was 
observed in meta-analyses results when studies were stratified by design type, that is, cohort 
versus case–control. Nor were meaningful differences in the meta-analyses results observed 
when the analyses were restricted to include only studies based on populations with a 
mixture of both type 1 and type 2 diabetes. OR estimates based on a random-effects meta-
analysis in which estimates were developed using approximate maximum likelihood 
methods were virtually identical to those produced using the Bayesian approach (Appendix 
Figure 1, available online). Limiting studies to those published between 2000 and 2012 led 
to an estimated median posterior OR of 3.6 (95% CrI=2.6, 4.8), which is consistent with the 
estimate based on all studies of 3.8 (95% CrI=3.0, 4.9).
Conclusions
Interventions identifying and increasing the number of women with PGDM who achieve 
glycemic control prior to pregnancy could substantially reduce the number of CHD-affected 
infants each year. Assuming complete elimination of CHD risk due to PGDM, about 2670 
cases of CHDs may be prevented annually in the U.S. Among some specific CHDs, 435 
cases of AVSD, 140 cases of coarctation of the aorta, 75 cases of HLHS, and 230 cases of 
ToF could potentially be prevented in the U.S. annually.
The prevalence of diabetes increased significantly among young adults (aged 20–34 years) 
from 1988–1994 to 2005–2010.48 Projections of diabetes incidence among those aged 
younger than 20 years indicates that the number with type 1 and type 2 diabetes will triple 
and quadruple by 2050, respectively.49 A greater burden of disease at younger ages will 
place more women at risk prior to pregnancy. Presence of PGDM and hyperglycemia has 
important maternal and fetal health consequences beyond the development of CHDs. 
Compared to women without PGDM, women with PGDM are at increased risk of having 
infants affected by noncardiac birth defects,7,50 macrosomia,51 preterm birth,51,52 
spontaneous abortion,21 and perinatal mortality.51,53
If all reproductive-aged women with PGDM planned their pregnancies, sought 
preconception care, and achieved glycemic control prior to and throughout pregnancy, they 
could reduce the risk of CHDs as well as other adverse maternal and fetal outcomes. 
However, there are challenges to achieving this reduction. First, about 0.5%–1% of all 
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women of reproductive age in the U.S. (310,000–625,000 women) have undiagnosed 
diabetes.24,29,54 These women are not receiving diabetes management prior to a potential 
pregnancy and are likely not under glycemic control. Lack of glycemic control will cause 
these women to remain at increased risk for congenital anomalies and other adverse 
maternal and fetal outcomes if they become pregnant. Second, despite recommendations that 
women with diabetes plan their pregnancies and receive preconception care,55,56 fewer than 
half of women with diabetes who become pregnant plan their pregnancies, and women with 
diabetes may have poorer contraceptive practices than women without diabetes.23,57–59 
Furthermore, although achieving glycemic control is possible for some women, not all 
women will achieve glycemic control prior to pregnancy, even with preconception care.21,60 
Generally, only 40%–60% of women with diagnosed PGDM achieve glycemic control prior 
to and early in pregnancy.22,23 Improved screening and diagnosis of diabetes among women 
who are overweight with additional risk factors for diabetes (e.g., physical inactivity or first-
degree relative with diabetes),61 coupled with improved diabetes management and access to 
care both at preconception and throughout pregnancy may prevent numerous adverse 
outcomes associated with PGDM.13,19,21,60
The analysis was subject to several limitations. First, the Bayesian meta-analyses for 
individual CHDs were based on limited data and risk of bias was not formally assessed 
owing to the limited number of studies. However, sensitivity analyses indicated that results 
were robust to prior assumptions on the true values of the PGDM–CHD association and on 
the level of heterogeneity among studies (Appendix, available online). Second, 
hyperglycemia due to PGDM was assumed to be the only cause of PGDM-related CHDs 
and achievement of glycemic control prior to pregnancy was assumed to eliminate the 
PGDM–CHD risk. The true biological mechanism of the PGDM–CHD association is 
unknown and could arise from multiple factors.13 Third, because of limited data, risk of 
having a CHD-affected pregnancy was assumed to be the same regardless of the presence of 
type 1 or type 2 diabetes.62 However, type 1 and type 2 diabetes may differentially impact 
the risk of CHDs. Currently, women with type 2 PGDM tend to be older during pregnancy, 
more socially disadvantaged, overweight or obese, and report later entry into prenatal care 
compared to women with type 1 PGDM.20 In addition, as the studies contributing data to the 
meta-analysis spanned a wide range of years, differences in the presentation of diabetes 
could have existed; however, a supplemental analysis indicated that the summary OR was 
not impacted by the changing prevalence of type 1 and type 2 diabetes in the population. 
Fourth, the present models assumed no confounding by maternal factors, such as age and 
parity; however, confounding by maternal age and parity was not expected.63,64 These 
limitations could have biased the estimate of the true PAFs and thus overstated or 
understated the impact of achieving glycemic control prior to pregnancy.
Despite these limitations, the analysis benefited from strict inclusion criteria and abstraction 
of raw data from the published literature. Uncertainty and heterogeneity between studies was 
accounted for using a Bayesian procedure. Additionally, sensitivity analyses examined the 
assumptions that type 1 and type 2 PGDM impacted risk of CHDs in the same way, and that 
studies spanning all years could be used to examine the PGDM–CHD association despite 
changes in presentation, treatment, and management of PGDM. These sensitivity analyses 
suggested that the estimates are robust and stable.
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Findings from this meta-analysis and modeling project suggest that effective preconception 
care for women with PGDM could reduce the number of cases of CHD in the U.S. each 
year. In addition, considerable reductions in the number of individual, serious CHDs such as 
ToF and HLHS could be achieved. These results underscore the need for improved 
screening for PGDM, preconception care, and pregnancy planning to ensure that women 
with PGDM are under proper care for optimal pregnancy outcomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Systematic review. Literature review and exclusions for the association between 
pregestational diabetes and congenital heart defects for systematic review and meta-analysis, 
publications through December 2012.
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Table 1
Birth Prevalence and Estimated Annual Number of U.S. Cases for Selected Congenital Heart Defect 
Outcomes
Defect
Prevalence per 
10,000 live births
95% CI for 
prevalence
Estimated annual 
number of U.S. 
cases
95% CI for annual 
number of U.S. cases
Total congenital heart defectsa 81.4 78.6, 84.2 32,182 31,075, 33,301
 Non-Hispanic whiteb 97.3 91.5, 103.0 20,878 19,642, 22,114
 Non-Hispanic blackb 79.8 74.6, 84.9 4,645 4,347, 4,943
 Hispanicb 91.5 83.8, 99.3 8,402 7,682, 9,113
Atrioventricular septal defectsc 4.7 4.6, 5.0 1,858 1,759, 1,961
 Non-Hispanic whiteb 4.1 2.9, 5.3 884 629, 1,140
 Non-Hispanic blackb 5.1 3.8, 6.4 296 221, 372
 Hispanicb 2.1 0.9, 3.2 190 82, 297
Coarctation of the aortaa 4.5 2.9, 4.9 1,767 1,147, 1,937
 Non-Hispanic whiteb 5.5 4.1, 6.8 1,173 878, 1,467
 Non-Hispanic blackb 4.0 2.8, 5.1 231 164, 298
 Hispanicb 3.6 2.1, 5.2 332 190, 474
Hypoplastic left heart syndromec 2.3 2.2, 2.5 909 850, 969
 Non-Hispanic whiteb 2.0 1.1, 2.8 423 246, 600
 Non-Hispanic blackb 2.5 1.6, 3.4 146 93, 199
 Hispanicb 1.9 0.8, 3.0 174 71, 276
Tetralogy of Fallotc 4.0 3.8, 4.2 1,570 1,491, 1,649
 Non-Hispanic whiteb 4.6 3.3, 5.8 980 711, 1,249
 Non-Hispanic blackb 5.5 4.2, 6.9 321 243, 400
 Hispanicb 3.4 1.9, 4.9 316 177, 454
Transposition of the great arteriesc 3.0 2.8, 3.2 1,186 1,119, 1,253
 Non-Hispanic whiteb 2.2 1.4, 3.1 481 292, 669
 Non-Hispanic blackb 2.3 1.5, 3.2 136 84, 187
 Hispanicb 2.6 1.3, 3.9 237 117, 357
a
From Reller et al., 2008.1
b
From Bjornard et al., 2013.40
c
From Parker et al., 2010.39
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Table 2
Summary OR, Population Attributable Fraction, and Preventable Cases of Congenital Heart Defects
Congenital heart defect
Summary OR 
(95% CrI)b
Attributable fraction 
(%) (95% UI)c
Annual preventable number of CHD (95% UI)a
100% Elimination of risk 
associated with PGDM
50% Reduction in risk 
associated with PGDMd
All congenital heart defects 3.8 (3.0, 4.9) 8.3 (5.6, 11.8) 2,670 (1,795, 3,795) 1,335 (900, 1,900)
 Non-Hispanic white 7.1 (4.2, 11.4) 1,480 (880, 2,385) 740 (440, 1,195)
 Non-Hispanic black 11.5 (7.4, 17.1) 535 (340, 800) 270 (170, 400)
 Hispanic 9.5 (5.3, 16.2) 795 (440, 1,370) 400 (220, 685)
Atrioventricular septal defects 10.6 (4.7, 20.9) 23.4 (10.6, 40.0) 435 (195, 745) 220 (100, 375)
 Non-Hispanic white 20.4 (8.5, 38.1) 180 (70, 355) 90 (35, 180)
 Non-Hispanic black 30.6 (14.1, 49.8) 90 (40, 155) 45 (20, 80)
 Hispanic 26.1 (11.1, 46.5) 50 (15, 105) 25 (20, 80)
Coarctation of the aorta 3.7 (1.7, 7.4) 7.9 (2.1, 17.6) 140 (35, 315) 70 (20, 160)
 Non-Hispanic white 6.7 (1.8, 15.8) 80 (20, 195) 40 (10, 100)
 Non-Hispanic black 11.0 (2.9, 24.1) 25 (5, 60) 15 (5, 30)
 Hispanic 8.9 (2.4, 21.8) 30 (5, 75) 15 (5, 40)
Hypoplastic left heart syndrome 3.7 (1.5, 8.9) 8.0 (1.6, 20.4) 75 (15, 185) 40 (10, 95)
 Non-Hispanic white 6.9 (1.3, 18.8) 30 (55, 85) 15 (5, 45)
 Non-Hispanic black 11.2 (2.2, 27.5) 15 (5, 45) 10 (5, 25)
 Hispanic 9.1 (1.7, 24.6) 15 (0, 50) 10 (0, 25)
Tetralogy of Fallot 6.5 (3.3, 11.8) 14.8 (6.6, 26.3) 230 (105, 415) 115 (55, 210)
 Non-Hispanic white 12.8 (5.4, 24.4) 125 (50, 250) 60 (25, 125)
 Non-Hispanic black 20.0 (8.9, 34.7) 65 (30, 115) 35 (15, 60)
 Hispanic 16.7 (7.0, 32.0) 50 (20, 115) 25 (10, 60)
Transposition of the great arteries 4.8 (2.7, 8.3) 10.9 (5.1, 19.8) 130 (60, 235) 65 (30, 120)
 Non-Hispanic white 9.4 (4.0, 18.6) 45 (15, 100) 25 (10, 50)
 Non-Hispanic black 15.0 (6.8, 27.0) 20 (10, 40) 10 (5, 20)
 Hispanic 12.4 (5.2, 24.9) 30 (10, 65) 15 (5, 35)
aAll estimates and uncertainty intervals rounded to nearest multiple of five.
b
Posterior estimates for the summary OR estimated using Bayesian meta-analyses.
cAttributable fraction estimated based on race-specific estimates of the prevalence of diabetes. Uncertainty intervals estimated via Monte Carlo 
sampling
d
Estimated by multiplying the attributable fraction by half of the estimated prevalence.
CHD, congenital heart defect; CrI, credible interval; PGDM, pregestational diabetes mellitus; UI, uncertainty interval.
Am J Prev Med. Author manuscript; available in PMC 2016 February 01.
